# A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

> **NCT00685360** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 481 (actual)

## Conditions studied

- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug Resistant
- Extensively Drug-Resistant Tuberculosis

## Interventions

- **DRUG:** Delamanid
- **DRUG:** Optimized Background Regimen (OBR)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00685360
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-08
- **Primary completion:** 2010-06-11
- **Final completion:** 2010-06-11
- **Target enrollment:** 481 (ACTUAL)
- **Last updated:** 2021-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00685360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00685360, "A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00685360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*